Regeneron and Sanofi have announced an independent data safety monitoring committee recommended that its Phase II/III study repurposing Kevzara for Covid-19 only continue treating ‘critical’ patients – it had previously also enrolled and treated ‘severe’ patients.

Critical patients are those who require mechanical ventilation, high flow oxygenation or treatment in the intensive care unit, while severe patients are those who required oxygen supplementation without mechanical ventilation or high flow oxygenation.

This is because when severe and critical groups were combined Kevzara had “no notable benefit on clinical outcomes”. Also, analysis identified there were a negative trends for most outcomes in the severe group, compared to positive trends for all outcomes in the critical group, according to a release.

In addition, the committee recommended the discontinuation of the lower, 200mg dose of Kevzara arm of the trial.

Kevzara is already approved for moderately to severely activated rheumatoid arthritis patients who have not responded to prior therapy. It is an interleukin-6 inhibitor; these drugs are believed to have an effect at reducing the cytokine storm associated with severely-ill Covid-19 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.